NEW YORK (GenomeWeb) – Natera and the Feinstein Institute for Medical Research will partner to conduct research on cell-free circulating tumor DNA in order to detect, diagnose, and monitor cancer.

Natera will provide funding to the Feinstein Institute, which will contribute blood and tissue samples. Natera will develop technology for detecting ctDNA.

"Our vision is to enable cancer detection across multiple tumor types that will have the same key features as our prenatal tests: early, accurate, and non-invasive," said Natera CEO Matthew Rabinowitz in a statement.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Cell this week: map of human protein interactions, mutant phenotype variability in organisms of the same species from different genetic backgrounds, and more.

Critics call the Fred Hutchinson Cancer Research Center's Gary Gilliland's prediction of cancer cures within 10 years "out of touch with reality" and "irresponsible."

Ivan Oransky discusses the need for reproducibility research at The Conversation.

The San Diego Union-Tribune posts videos from Biocom's Speaker Series with Illumina's Jay Flatley, who discusses Roche's failed hostile takeover bid.